| everolimus / Generic mfg. |
NCT01412515 / 2007-000974-22: A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma |
|
|
| Terminated | 2 | 11 | Europe | everolimus | Institut National de la Santé Et de la Recherche Médicale, France | Kaposi Sarcoma | 05/11 | 05/11 | | |
NCT01048723: Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas |
|
|
| Terminated | 2 | 2 | US | RAD001, everolimus | H. Lee Moffitt Cancer Center and Research Institute, Novartis | Sarcoma | 10/11 | 10/11 | | |
| Completed | 2 | 41 | RoW | RAD001, Everolimus | Asan Medical Center, Novartis | Soft Tissue Sarcomas, Bone Sarcomas | 01/13 | | | |
|
SERIO, NCT01804374: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma |
|
|
| Completed | 2 | 38 | Europe | Sorafenib, BAY 43-9006, Nexavar, Everolimus, RAD001, Afinitor, Certican | Italian Sarcoma Group | Metastatic Osteosarcoma, Relapsed Osteosarcoma | 12/14 | 12/14 | | |
|
| Completed | 2 | 71 | Europe | Everolimus, RAD001 | Novartis Pharmaceuticals | Progressive Sarcoma | 05/17 | 05/17 | | |
NCT01661283: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors |
|
|
| Completed | 2 | 25 | US | everolimus, Afinitor, everolimus, bevacizumab, Avastin | Sarcoma Alliance for Research through Collaboration, Novartis Pharmaceuticals, Genentech, Inc., United States Department of Defense | Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma | 06/17 | 12/17 | | |
|
CHONRAD, NCT02008019: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas |
|
|
| Suspended | 2 | 57 | Europe | Everolimus 2.5 mg/day, Afinitor; Votubia; RAD-001, Everolimus 10 mg/day | Centre Leon Berard | Chondrosarcoma | 08/18 | 08/19 | | |
NCT01281865: Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma |
|
|
| Completed | 1b/2 | 14 | US | diagnostic laboratory biomarker analysis, everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, imatinib mesylate, CGP 57148, Gleevec, Glivec | National Cancer Institute (NCI) | Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | 10/13 | 10/13 | | |
|
NCT00457964: RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM |
|
|
| Completed | 1/2 | 36 | US | RAD001 | Children's Hospital Medical Center, Cincinnati, Novartis Pharmaceuticals | Tuberous Sclerosis, Lymphangioleiomyomatosis | 07/13 | 07/13 | | |
NCT00792766: Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) |
|
|
| Completed | 1/2 | 20 | US | everolimus (RAD001), RAD001 | Children's Hospital Medical Center, Cincinnati, Novartis | Tuberous Sclerosis, Angiolipoma | 09/13 | 09/13 | | |
